Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An open, observational health economic study to estimate marginal cost and health consequences of replacing conventional Parkinsons disease therapy with intraduodenal levodopa administered continuously

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levodopa (drug), intraduodenal administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of of idiopathic Parkinsons disease
* Motor fluctuations despite optimised per oral treatment

Exclusion Criteria

* Severe dementia, confusion, psychosis or depression
* Patients with contraindications against levodopa treatment

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christofer Lundqvist

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christofer Lundqvist, PhD, M.D.

Role: PRINCIPAL_INVESTIGATOR

HØKH - Helse Ost Health Services Research Centre, Akershus University Hospital, Norway

Antonie Beiske, PhD, M.D.

Role: PRINCIPAL_INVESTIGATOR

Dept Neurology, Akershus University Hospital, Norway

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Akershus University Hospital

Nordbyhagen, , Norway

Site Status

Dept Neurology, Ulleval University Hospital

Oslo, , Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Duo-HRQoL-2

Identifier Type: -

Identifier Source: org_study_id

Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit